Potential drug-drug interactions and adverse drug reactions in patients with liver cirrhosis

European Journal of Clinical Pharmacology

Volumn 68, Issue 2, 2012, Pages 179-188

  Franz, Carmen C ^a   Egger, Sabin ^a   Born, Christa ^a   Rätz Bravo, Alexandra E ^a   Krähenbühl, Stephan ^a  

^a UNIVERSITY HOSPITAL BASEL   (Switzerland)

Author keywords

Adverse drug reactions; Dose adjustment; Drug drug interactions; Liver cirrhosis

Indexed keywords

ACETYLSALICYLIC ACID; ALLOPURINOL; AMIODARONE; ANTICOAGULANT AGENT; BENZODIAZEPINE DERIVATIVE; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; CLOPIDOGREL; DALTEPARIN; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; DIURETIC AGENT; FUROSEMIDE; IBUPROFEN; INSULIN; LISINOPRIL; NARCOTIC ANALGESIC AGENT; NONSTEROID ANTIINFLAMMATORY AGENT; PERINDOPRIL; PHENOBARBITAL; PHENPROCOUMON; POTASSIUM CHLORIDE; POTASSIUM SPARING DIURETIC AGENT; PROPRANOLOL; REPAGLINIDE; SARTAN DERIVATIVE; SPIRONOLACTONE; SULFONYLUREA DERIVATIVE; TORASEMIDE; UNINDEXED DRUG; VALSARTAN; VENLAFAXINE;

ADULT; ADVERSE DRUG REACTION; AGE; AGED; ANEMIA; ARTICLE; ASCITES; BLEEDING; BLEEDING ASSOCIATED ANEMIA; BLOOD DISEASE; BRADYCARDIA; CARDIAC DEPRESSION; CARDIOVASCULAR DISEASE; COMORBIDITY; CONFUSION; CROSS-SECTIONAL STUDY; DIGESTIVE SYSTEM DISEASE; DISEASE SEVERITY; FEMALE; GASTROINTESTINAL DISEASE; GASTROINTESTINAL HEMORRHAGE; HEART DISEASE; HOSPITAL ADMISSION; HUMAN; HYPERKALEMIA; HYPOGLYCEMIA; HYPONATREMIA; HYPOTENSION; KIDNEY DYSFUNCTION; KIDNEY FAILURE; LIVER CIRRHOSIS; LOW DRUG DOSE; MAJOR CLINICAL STUDY; MALE; MENTAL DISEASE; METABOLIC DISORDER; NEPHROTOXICITY; NEUROLOGIC DISEASE; POLYPHARMACY; PRIORITY JOURNAL; RESPIRATION DEPRESSION; RETROSPECTIVE STUDY; SYNCOPE; THROMBOCYTOPENIA; UNSPECIFIED SIDE EFFECT; URINARY TRACT DISEASE;

ADULT; AGED; AGED, 80 AND OVER; COMORBIDITY; CROSS-SECTIONAL STUDIES; DRUG INTERACTIONS; DRUG TOXICITY; FEMALE; HOSPITALIZATION; HUMANS; LIVER CIRRHOSIS; MALE; MIDDLE AGED; POLYPHARMACY; RETROSPECTIVE STUDIES; YOUNG ADULT;

EID: 84857040487     PISSN: 00316970     EISSN: 14321041     Source Type: Journal    
DOI: 10.1007/s00228-011-1105-5     Document Type: Article

References (30)

1. DA Leon J McCambridge 2006 Liver cirrhosis mortality rates in Britain from 1950 to 2002: an analysis of routine data Lancet 367 52 56 16399153 10.1016/S0140-6736(06)67924-5 (Pubitemid 43038670)
2. F Delco L Tchambaz R Schlienger J Drewe S Krahenbuhl 2005 Dose adjustment in patients with liver disease Drug Saf 28 529 545 15924505 10.2165/00002018-200528060-00005 1:CAS:528:DC%2BD2MXmsVGhu7c%3D (Pubitemid 41003057)
3. MJ Zuckerman IS Menzies H Ho GG Gregory NA Casner RS Crane, et al. 2004 Assessment of intestinal permeability and absorption in cirrhotic patients with ascites using combined sugar probes Dig Dis Sci 49 621 626 15185867 10.1023/B:DDAS.0000026307.56909.21 (Pubitemid 38992551)
4. TF Blaschke PC Rubin 1979 Hepatic first-pass metabolism in liver disease Clin Pharmacokinet 4 423 432 391462 10.2165/00003088-197904060-00002 1:STN:280:DyaL3c%2FptVKltg%3D%3D (Pubitemid 10210050)
5. K Vyas B Gala P Sawant HS Das PM Kulhalli SS Mahajan 2002 Assessment of portal hemodynamics by ultrasound color Doppler and laser Doppler velocimetry in liver cirrhosis Indian J Gastroenterol 21 176 178 12416745
6. A Adedoyin PA Arns WO Richards GR Wilkinson RA Branch 1998 Selective effect of liver disease on the activities of specific metabolizing enzymes: investigation of cytochromes P450 2C19 and 2D6 Clin Pharmacol Ther 64 8 17 9695714 10.1016/S0009-9236(98)90017-0 1:CAS:528:DyaK1cXltlarsr8%3D (Pubitemid 28377325)
7. J George M Murray K Byth GC Farrell 1995 Differential alterations of cytochrome P450 proteins in livers from patients with severe chronic liver disease Hepatology 21 120 128 7806144 1:STN:280:DyaK2M7gsVOnuw%3D%3D
8. I Tegeder J Lotsch G Geisslinger 1999 Pharmacokinetics of opioids in liver disease Clin Pharmacokinet 37 17 40 10451781 10.2165/00003088-199937010- 00002 1:CAS:528:DyaK1MXls1Wiu7s%3D (Pubitemid 29366758)
9. AJ MacGilchrist GG Birnie A Cook G Scobie T Murray G Watkinson, et al. 1986 Pharmacokinetics and pharmacodynamics of intravenous midazolam in patients with severe alcoholic cirrhosis Gut 27 190 195 2936661 10.1136/gut.27.2.190 1:STN:280:DyaL287jslKqsQ%3D%3D (Pubitemid 16124115)
10. P Gines V Arrovo J Rodes 1992 Pharmacotherapy of ascites associated with cirrhosis Drugs 43 316 332 1374317 10.2165/00003495-199243030-00003 1:STN:280:DyaK383kvFahtA%3D%3D
11. A Krahenbuhl-Melcher R Schlienger M Lampert M Haschke J Drewe S Krahenbuhl 2007 Drug-related problems in hospitals: a review of the recent literature Drug Saf 30 379 407 17472418 10.2165/00002018-200730050-00003 (Pubitemid 46740336)
12. DW Cockcroft MH Gault 1976 Prediction of creatinine clearance from serum creatinine Nephron 16 31 41 1244564 10.1159/000180580 1:STN:280: DyaE28%2FnsF2isw%3D%3D
13. Child CG, Turcotte JG (1964) Surgery and portal hypertension. In: Child C (ed) The liver and portal hypertension. Saunders, Philadelphia, pp 50-64
14. SS Egger S Meier C Leu S Christen A Gratwohl S Krahenbuhl, et al. 2010 Drug interactions and adverse events associated with antimycotic drugs used for invasive aspergillosis in hematopoietic SCT Bone Marrow Transplant 45 1197 1203 19946342 10.1038/bmt.2009.325 1:CAS:528:DC%2BC3cXosVGgtb8%3D
15. MI Lucena RJ Andrade G Tognoni R Hidalgo FS De La Cuesta 2002 Multicenter hospital study on prescribing patterns for prophylaxis and treatment of complications of cirrhosis Eur J Clin Pharmacol 58 435 440 12242604 10.1007/s00228-002-0474-1 1:CAS:528:DC%2BD38XntFensbY%3D
16. MI Lucena RJ Andrade G Tognoni R Hidalgo F Sanchez de la Cuesta 2003 Drug use for non-hepatic associated conditions in patients with liver cirrhosis Eur J Clin Pharmacol 59 71 76 12684727 (Pubitemid 36702762)
17. J Lazarou BH Pomeranz PN Corey 1998 Incidence of adverse drug reactions in hospitalized patients: a meta-analysis of prospective studies JAMA 279 1200 1205 9555760 10.1001/jama.279.15.1200 1:STN:280:DyaK1c3hsFSnsQ%3D%3D (Pubitemid 28193431)
18. CS van der Hooft JP Dieleman C Siemes AJ Aarnoudse KM Verhamme BH Stricker, et al. 2008 Adverse drug reaction-related hospitalisations: a population-based cohort study Pharmacoepidemiol Drug Saf 17 365 371 18302300 10.1002/pds.1565 (Pubitemid 351566352)
19. M Pirmohamed S James S Meakin C Green AK Scott TJ Walley, et al. 2004 Adverse drug reactions as cause of admission to hospital: prospective analysis of 18 820 patients BMJ 329 15 19 15231615 10.1136/bmj.329.7456.15 (Pubitemid 38869995)
20. K Fattinger M Roos P Vergeres C Holenstein B Kind U Masche, et al. 2000 Epidemiology of drug exposure and adverse drug reactions in two Swiss departments of internal medicine Br J Clin Pharmacol 49 158 167 10671911 10.1046/j.1365-2125.2000.00132.x 1:CAS:528:DC%2BD3cXht1altL0%3D (Pubitemid 30068294)
21. DC Classen SL Pestotnik RS Evans JP Burke 1991 Computerized surveillance of adverse drug events in hospital patients JAMA 266 2847 2851 1942452 10.1001/jama.1991.03470200059035 1:STN:280:DyaK38%2Fks1Kisw%3D%3D
22. RD Herr EM Caravati LS Tyler E Iorg MS Linscott 1992 Prospective evaluation of adverse drug interactions in the emergency department Ann Emerg Med 21 1331 1336 1416328 10.1016/S0196-0644(05)81897-9 1:STN:280: DyaK3s%2Fjs1KktA%3D%3D
23. AE Ratz Bravo L Tchambaz A Krahenbuhl-Melcher L Hess RG Schlienger S Krahenbuhl 2005 Prevalence of potentially severe drug-drug interactions in ambulatory patients with dyslipidaemia receiving HMG-CoA reductase inhibitor therapy Drug Saf 28 263 275 15733030 10.2165/00002018-200528030-00007 (Pubitemid 40364892)
24. A Corsonello C Pedone F Corica C Mussi P Carbonin R Antonelli Incalzi, et al. 2005 Concealed renal insufficiency and adverse drug reactions in elderly hospitalized patients Arch Intern Med 165 790 795 15824299 10.1001/archinte.165. 7.790 (Pubitemid 40569433)
25. MA Papadakis AI Arieff 1987 Unpredictability of clinical evaluation of renal function in cirrhosis. Prospective study Am J Med 82 945 952 3578363 10.1016/0002-9343(87)90156-2 1:STN:280:DyaL2s3htVaqtg%3D%3D
26. P Angeli A Gatta L Caregaro F Menon D Sacerdoti C Merkel, et al. 1990 Tubular site of renal sodium retention in ascitic liver cirrhosis evaluated by lithium clearance Eur J Clin Invest 20 111 117 2108033 10.1111/j.1365-2362.1990. tb01800.x 1:STN:280:DyaK3c3gtFWmtQ%3D%3D (Pubitemid 20056282)
27. O Amir Y Hassan A Sarriff A Awaisu N Abd Aziz O Ismail 2009 Incidence of risk factors for developing hyperkalemia when using ACE inhibitors in cardiovascular diseases Pharm World Sci 31 387 393 19255869 10.1007/s11096-009- 9288-x 1:CAS:528:DC%2BD1MXltl2ktr0%3D
28. D Sacerdoti M Bolognesi C Merkel P Angeli A Gatta 1993 Renal vasoconstriction in cirrhosis evaluated by duplex Doppler ultrasonography Hepatology 17 219 224 8428719 1:STN:280:DyaK3s7lsVKlug%3D%3D (Pubitemid 23046692)
29. G Wensing E Lotterer I Link EG Hahn WE Fleig 1997 Urinary sodium balance in patients with cirrhosis: relationship to quantitative parameters of liver function Hepatology 26 1149 1155 9362355 1:STN:280:DyaK1c%2Fis1Kkug%3D%3D (Pubitemid 27509296)
30. V De Ledinghen D Heresbach O Fourdan P Bernard MP Liebaert-Bories JB Nousbaum, et al. 1999 Anti-inflammatory drugs and variceal bleeding: a case-control study Gut 44 270 273 9895389 10.1136/gut.44.2.270 (Pubitemid 29119373)